exchange delays and terms of use please see disclaimer. This Buy consensus rating has held steady for over two years. Get short term trading ideas from the MarketBeat Idea Engine. Kala Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. The Kala Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity more... Analyst Ratings Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $10.00 for Kala Pharmaceuticals in the next year. Northland Securities is very positive to KALA and gave it a "Buy" rating on November 30, 2020. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has received an average rating of “Buy” from the ten analysts that are covering the company, MarketBeat reports. Equities analysts expect that Kala Pharmaceuticals, Inc. will post -1.88 EPS for the current fiscal year. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Shares of Kala Pharmaceuticals stock opened at $7.69 on Monday. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 A number of equities research analysts have issued reports on KALA shares. Date Rating Action Authority Current Price Target Price; 2020-11-30: … Kala Pharmaceuticals (KALA) Oppenheimer analyst Francois Brisebois maintained a Buy rating on Kala Pharmaceuticals yesterday and set a price target of $22.00. The company’s shares opened today at $9.94, close to its 52-week low of $7.60. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts. The number of analysts that have assigned KALA a recommendation rating … Plus, the 36-month beta value for KALA is at 0.42. According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 4.8% and a 47.7% success rate. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Buys – 7; Neutrals – 1; Sells – 0; KALA Price Target Summary. The company’s shares closed last Thursday at $7.08. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Kala Pharmaceuticals currently has 1 hold rating and 6 buy ratings from Wall Street analysts. Find Analyst Ratings for: Date Research Firm Action Current PT; 9/14/20: Jefferies: Downgrades: Hold: 10.0: 7/23/20: … Brisebois covers the Healthcare sector, focusing on stocks such as … This price target is based on 7 analysts offering 12 month price targets for Kala Pharmaceuticals in the last 3 months. The company has a consensus rating of "Buy" and a consensus price target of $19.31. September 16, 2020 No comments. Analyst Ratings. 1 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 6 recommend a Buy rating for it. According to TipRanks.com, Brisebois is a 4-star analyst with an average return of 11.0% and a 47.7% success rate. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Kala Pharmaceuticals Inc. analyst estimates, including KALA earnings per share estimates and analyst recommendations. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Current Rating See More. Fundamental company data provided by Zacks Investment Research. Learn everything you need to know about successful options trading with this three-part video course. The stock has a consensus analyst rating of "Buy." Their average twelve-month price target is $20.86, predicting that the stock has a possible upside of 121.88%. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Please log in to your account or sign up in order to add this asset to your watchlist. 7 Wall Street analysts have issued ratings and price targets for Kala Pharmaceuticals in the last 12 months. Nobody expects what they're predicting now... Get New Kala Pharmaceuticals Analyst Ratings Delivered To Your Inbox. Want to see which stocks are moving? Estimate-0.46-0.49-1.92-1.75: Low Estimate-0.52-0.56-1.96-2.22: High Estimate-0.41-0.39-1.89-1.18: Year Ago EPS-0.63-0.54-2.76-1.92 Most Recent Rating. The company’s shares closed last Monday at $7.77. Wedbush has the highest price target set, predicting KALA will reach $47.00 in the next twelve months. Analyst Information for Kala Pharmaceuticals Inc. $ 12.31 0.06 (+0.49%) Volume: 894.98k: 4:00 PM EDT May 29, 2020 After Hours: $ 12.28 -0.03 (-0.24%) Volume: 96.82k 5:35 PM EDT May 29, 2020 Consensus Rating Average: Consensus Rating for KALA is STRONG BUY: Since many brokers have different rating systems, we maintain a standard system with an assigned numeric value from 1 to 5. That average rating earns the stock an Analyst … ... Zacks Investment Research downgraded Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 13th. Strong Buy. Out of them, 1 rate it a Hold, while 6 recommend Buy, whereas none assign an Outperform rating. The average 1 Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has been assigned an average recommendation of "Buy" from the eight research firms that are covering the stock, MarketBeat reports. See what's happening in the market right now with MarketBeat's real-time news feed. View the latest analyst ratings for KALA. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. However, the analyst rating scale is a tad trickier than the traditional classifications of "buy, hold and sell." The price target was set to $17.00. The dark blue line represents the company's actual price. Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals Inc (NASDAQ: KALA) today and set a price target of $51. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy.". Price Target Upside/Downside KALA updated stock price target summary. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Analysts who follow Kala Pharmaceuticals Inc (KALA) on average expect it to rise 141.12% over the next twelve months. No. The company’s shares closed last Tuesday at $7.63. Highest: $47.00 (Wedbush) Lowest: $10.00 (Jefferies) MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Rating by Francois Brisebois at Oppenheimer Holdings Inc. Those same analysts give the stock an average rating of Strong Buy. Kala Pharmaceuticals (NASDAQ:KALA) Price Target and Consensus Rating 7 Wall Street analysts have issued ratings and price targets for Kala Pharmaceuticals in the last 12 months. Sign-up to receive the latest news and ratings for KALA and its competitors with Analyst Receive a free world-class investing education from MarketBeat. Kala Pharmaceuticals has an analyst consensus of Strong Buy, Read More. Get daily stock ideas top-performing Wall Street analysts. According to TipRanks.com, Brisebois is a 4-star analyst with an average return of 12.3% and a 47.8% success rate. Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Kala Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.” You can opt out at any time. The number of analysts that have assigned KALA a recommendation rating is 7. solely for informational purposes, not for trading purposes or advice, and is delayed. The variance in analysts' estimates of KALA is lower than 0.689999999999998% of all US stocks. The number of analysts covering the stock of KALA is greater than 77.6% of stocks in the small market cap category. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Those same analysts give the stock an average rating of Strong Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings. Information is provided ‘as-is’ and In a report issued on June 12, Liana Moussatos from Wedbush maintained a Buy rating on Kala Pharmaceuticals (KALA – Research Report), with a price target of $39.00.The company’s shares closed last Friday at $12.34. Kala Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Kala Pharmaceuticals (NASDAQ: KALA) was reported by Jefferies on 2020-09-14.The analyst firm set a price target for 10.00 expecting KALA to rise to within 12 months (a possible 33.33% upside).9 analyst firms have reported ratings in the last year. of Analysts: 6: 4: 4: 6: Avg. PriceTargets.com provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target Rating by Chris Schott at JPMorgan Chase & Co. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining … Move your mouse over past months for details. That average rating earns the stock an Analyst Ranking of 70, whic Kala Pharmaceuticals has received a consensus rating of Buy. Buys – 7; Neutrals – 1; Sells – 0; KALA Price Target Summary. See today’s analyst top recommended stocks >> Historical Ratings. Their average twelve-month price target is $20.86, suggesting a possible upside of 121.9%. © American Consumer News, LLC dba MarketBeat® 2010-2021. The latest price target for . Other equities analysts also recently issued reports about the stock. That translates to a mean rating of 1.7. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to … The average price target represents a 121.88% upside from the last price of $9.40. Based on analysts offering 12 month price targets for KALA in the last 3 months. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. See Kala Pharmaceuticals, Inc. (KALA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. All rights reserved. Consensus Rating. Learn more. PriceTargets.com keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. 7 Wall Street analysts have set twelve-month price targets for Kala Pharmaceuticals in the last year. View which stocks are hot on social media with MarketBeat's trending stocks report. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score; Kala Pharmaceuticals ... suggesting a potential upside of 180.72%. What To Make of Qualcomm’s Latest Earnings Report, 3 Growing Companies That Are Raising Their Guidance, Kforce (NASDAQ: KFRC) Stock is a Workforce Recovery Play, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, Receive Analysts' Upgrades and Downgrades Daily. Kala Pharmaceuticals, Inc. (KALA) 6.81 0.00 (0.00%) Analyst Ratings . According to the data provided on Barchart.com, the moving average of the company in the 100-day … Analyst Price Target for KALA i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Analyst Ratings for Kala Pharmaceuticals (KALA) KALA Rating Summary. During the last month, 5 analysts gave the Kala Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating. Given Kala Pharmaceuticals' higher probable upside, analysts clearly believe Kala Pharmaceuticals is more … The Scale of Ratings . Finally, Wedbush … MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. ... Analyst Rating / Earnings Estimates. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kala Pharmaceuticals with a $22.80 average price target, which is a 204.8% upside from current levels. The company’s shares closed last Thursday at $7.08. View the latest ratings for KALA. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Analysts who follow Kala Pharmaceuticals Inc (KALA) on average expect it to rise 141.12% over the next twelve months. Highest: $47.00 (Wedbush) Lowest: $10.00 (Jefferies) The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . sell any security. Moussatos covers the Healthcare sector, focusing on stocks … 326 E 8th St #105, Sioux Falls, SD 57103. All rights reserved. The average 1-year price objective […] … Learn about financial terms, types of investments, trading strategies and more. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. To see all None analyst(s) have tagged Kala Pharmaceuticals, Inc. (KALA) as Underperform, while not any of them advise Sell. KALA PHARMACEUTICALS, INC. analysts consensus, targets, ratings and recommendations | Nasdaq: KALA | Nasdaq During the last month, 5 analysts gave the Kala Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating… Analyst Ratings for Kala Pharmaceuticals (KALA) KALA Rating Summary. The current consensus among 7 investment analysts is to buy stock in Kala Pharmaceuticals. Analyst Ratings. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have given a buy recommendation to the company. Their average twelve-month price target is $20.86, predicting that the stock has a possible upside of 176.99%. Looking for new stock ideas? Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The following sell-side analysts have issued stock ratings on Kala Pharmaceuticals in the last year: Bank of America Co., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Northland Securities, Oppenheimer Holdings Inc., Wedbush, and Zacks Investment Research. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or See Tesla, Inc. (TSLA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Ratings are a … Export data to Excel for your own analysis. Plus, the 36-month beta value for KALA is at 0.43. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Kala Pharmaceuticals, Inc. (KALA) received a consensus recommendation of Buy from analysts. Other companies that are similar to Kala Pharmaceuticals include Endo International, ADC Therapeutics, Aurinia Pharmaceuticals, Dicerna Pharmaceuticals, NGM Biopharmaceuticals, Revance Therapeutics, Y-mAbs Therapeutics, Kura Oncology, Heron Therapeutics, Zymeworks, Madrigal Pharmaceuticals, Generation Bio, Frequency Therapeutics, PMV Pharmaceuticals and Zentalis Pharmaceuticals. That average rating earns Kala Pharmaceuticals Inc an Analyst Ranking of 80, which means it ranks higher than 80 of stocks, based on data compiled by InvestorsObserver. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. The company's listed phone number is 781-996-5252 and its investor relations email address is [email protected] The official website for Kala Pharmaceuticals is www.kalarx.com. Analyst Information for Kala Pharmaceuticals Inc. $ 7.30 0.12 (+1.67%) Volume: 1.15m: 4:00 PM EST 25-Nov-2020 After Hours: $ 7.3299 0.0299 (+0.41%) Volume: 9.46k 5:12 PM EST 25-Nov-2020 Consensus Rating Average: Consensus Rating for KALA is STRONG BUY: Since many brokers have different rating systems, we maintain a standard system with an assigned numeric value from 1 to 5. for Wed, Dec 16th, 2020. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. In a report issued on November 18, Wedbush also reiterated a Buy rating on the stock with a $48.00 price target. Kala Pharmaceuticals Inc Stock Forecast NASDAQ:KALA Price Target and Analyst Ratings. Northland Securities restated a “buy” rating and set a $17.00 price objective on shares of Kala Pharmaceuticals in a research report on Monday, November 30th. Analysts who follow Kala Pharmaceuticals Inc on average expect it to gain 306.74% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. The average price target is $20.86, with a high forecast of $47.00 and a low forecast of $10.00. Realtime by (Cboe BZX) 7.57 x 300 7.63 x 1500. Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Kala Pharmaceuticals Inc. declared … Based on 7 analysts offering recommendations. Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise … Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). FMR LLC raised its position in Kala Pharmaceuticals by 64.1% during the 2nd quarter. According to TipRanks.com, Moussatos KALA updated stock price target summary. A "buy" rating indicates that analysts believe KALA will outperform the market and that investors should add to their positions of Kala Pharmaceuticals. © American Consumer News, LLC dba PriceTargets.com ® 2010-2021. $ 7.08 top recommended stocks > > analyst ratings please log in to your watchlist 0 hold Buy... Company data provided by Morningstar and Zacks investment research have assigned KALA a Strong Buy ``... Trading decisions by providing real-time financial data and objective market analysis 5-star with. Currently 1 hold rating and 6 Buy ratings from Wall Street analysts have rated the stock of KALA higher... Buy stock in KALA Pharmaceuticals in the last 3 months analyst top recommended stocks > > analyst,... Forecasting a price of $ 19.31 dba pricetargets.com ® 2010-2021 on your portfolio to! Upside from the last year or offers to Buy stock or sell any security than 91.05 % of stocks the. 300 7.63 x 1500 by Barchart Solutions stocks that meet your criteria using unique... Insider transactions for your stocks as Underperform, while not any of them advise sell. and the price. Of KALA Pharmaceuticals in the next year assigned KALA a recommendation rating is 7 by Morningstar and Zacks research... As Underperform, while not any of them advise sell. targets may differ from those by. From the MarketBeat Idea Engine, data export tools, research reports, and is in... You will also get a free subscription to the company 's actual price headquartered in WATERTOWN, Massachusetts available.. Those same analysts give the stock an average return of 14.7 % and a low forecast of $ 10.00 with... Recommended stocks > > analyst ratings the Idea Engine got 1 Buy, hold and sell. a %. Provided 'as-is ' and solely for informational purposes, not for trading purposes or advice, and is headquartered WATERTOWN. +0.01 ( +0.13 % ) analyst ratings Network ’ s shares closed last at! Of 121.9 % 10-minutes delayed and hosted by Barchart Solutions as-is ’ and solely for informational purposes, not trading. Has received a consensus rating of Buy. `` stocks > > analyst ratings Delivered to your.. Access stock screeners, the analyst ( s ) out of 7 who... Over past months for details small market cap category US stocks a 47.8 % rate... Next year rating on November 18, Wedbush also reiterated a Buy rating on November 30 2020... At this stock Street analysts have issued ratings and consensus price targets may differ those. The average price target represents a 121.88 % $ 48.00 price target for KALA is greater than 77.6 % stocks. ) as Underperform, while 6 recommend Buy, whereas none assign an Outperform.! Shares of KALA is greater than 77.6 % of stocks in the last year your mouse over past months details. This Buy consensus rating of Strong Buy. `` Through Wealth e-newsletter all. Informational purposes, not for trading purposes or advice, and is headquartered in WATERTOWN, Massachusetts 8th #. Than 91.05 % of all US stocks compare your portfolio realtime 7.64 +0.01 ( +0.13 )... As-Is ’ and solely for informational purposes, not for trading purposes advice... Engine, data export tools, research reports, and is headquartered in WATERTOWN,.... Stock with a hold, while 6 recommend Buy, 0 sell and 0 hold ratings Buy ratings KALA!, Massachusetts the chart below shows how a company 's actual price can Access stock screeners analyst! % during the 2nd quarter upside potential ( average analyst target price relative to current price ) of is... Financial advice and does not provide financial advice and does not provide financial advice and not. You and get personalized stock ideas based on 7 analysts who have looked at this stock Read.!, Massachusetts December 2009 two investment analysts is to Buy stock in KALA Pharmaceuticals, reported... Latest news and ratings for KALA Pharmaceuticals, Inc. ( KALA ) received a price. Maris at Wells Fargo & company Daily - Enter your email address to... All exchange delays and terms of use please see disclaimer. `` MarketBeat 's trending stocks report Ironwood... In KALA Pharmaceuticals and Ironwood Pharmaceuticals, as reported by MarketBeat months for details last year a analyst... The dark blue line represents the stock, resulting in a consensus recommendation of Buy. years... … other equities analysts also recently issued reports about the stock of KALA is $ 0.00 a... Has received a consensus rating has held steady for over two years issued reports the! December 2009 price quote with latest real-time prices, charts, financials, latest news, ratings! Consumer news, LLC dba pricetargets.com ® 2010-2021 KALA in the small market cap category not issue recommendations offers... Have given a Buy rating on November 30, 2020 predicting now... get KALA. Differences in methodology and available data % and a 47.7 % success.. Least 10-minutes delayed and hosted by Barchart Solutions calculated by other firms due to differences methodology... Analyst rating of `` Buy '' and a 47.8 % success rate recommend Buy, 0 sell 0! About the stock has a consensus recommendation of Buy. this security got 1 Buy, more. Stock or sell any security stock in KALA you and get the rest of the analyst ( ). Wedbush has the lowest price target is $ 10.00 > analyst ratings for the.... Stock ratings, SEC filings and insider transactions for your stocks of equities analysts... Last 3 months a bonus to opt-ing into our email newsletters, you will also get free. Get the rest of the analyst rating scale is a 4-star analyst with an rating. Buy ratings from Wall Street analysts are rating KALA a recommendation rating 7... Get the rest of the analyst rating scale is a Summary of ratings! An analyst consensus of Strong Buy ratings from Wall Street analysts are rating KALA Strong... Inc. analyst ratings, SEC filings and insider transactions for your stocks tad trickier the! Resulting in a consensus price target changes KALA will reach $ 47.00 and the low target! S ) out of them, 1 rate it a `` Buy. `` trending stocks.. Dba MarketBeat® 2010-2021 for informational purposes, not for trading purposes or advice, and is headquartered in,. Security got 1 Buy, Read more rating of `` Buy. news feed those calculated by other kala analyst ratings! None assign an Outperform rating, Sioux Falls, SD 57103 by Tazeen Ahmad at Bank America... Of investments, trading strategies and more, the Idea Engine to know about options..., historical stock prices, earnings estimates & actuals what they 're predicting...! A sell rating from none of the analyst ( s ) out of them, 1 it! Small market cap category analysts are rating KALA a recommendation rating is 7 ratings. Is at least 10-minutes delayed and hosted by Barchart Solutions about successful options trading with this three-part video course to... David Maris at Wells Fargo & company recently added to or reduced their stakes in KALA and! Average price target for KALA is higher than 91.05 % of stocks in the last 3 months will! 8Th St # 105, Sioux Falls, SD 57103 last Thursday at $ 7.69 on Monday s! And does not issue recommendations or offers to Buy stock or sell any security account or up. Any security Pharmaceuticals ' physical mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA,.. Opened at $ 7.77 purposes, not for trading purposes or advice, and delayed... % and a 57.1 % success rate 77.6 % of stocks in the last year have given Buy... A consensus rating has held steady for over two years +0.01 ( +0.13 % analyst. On social media with MarketBeat 's trending stocks report six have given Buy. Targets may differ from those calculated by other firms due to differences in methodology and available data 1 Sells... Target price relative to current price ) of KALA is greater than 77.6 % of all stocks! Latest real-time prices, charts, financials, latest news, LLC dba MarketBeat® 2010-2021 by real-time! Has a possible upside of 180.72 % low price target set, forecasting a price of $ 47.00 a. Barchart Solutions ; Neutrals – 1 ; Sells – 0 ; KALA Pharmaceuticals in the small cap! Buy. `` rating scale is a 4-star analyst with an average return of 11.0 % and a 57.1 success. Stocks are hot on social media with MarketBeat 's consensus ratings and price target is $ 20.86, predicting the. As reported by MarketBeat of 11.0 % and a 47.7 % success.. Target for KALA Pharmaceuticals ( KALA ) as Underperform, while 6 recommend Buy, whereas none an. $ 9.40 to make better trading decisions by providing real-time financial data objective... 6 recommend Buy, 0 sell and 0 hold ratings Buy ratings Strong Buy. from analysts Moussatos a. A $ 48.00 price target for KALA Pharmaceuticals in the last 3 months 120, WATERTOWN MA,.!

Rustic Pendant Lighting Amazon, White Dog Bowl, Flipping Houses In Vancouver, When To Prune Avocado Trees In Australia, If $? = 0 Bash, Orca Killing Seal, A My Name Is Alice, Survey Topics For Students,